Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Growth Metrics

Northwest Biotherapeutics (NWBO) Receivables (2016 - 2017)

Northwest Biotherapeutics' Receivables history spans 4 years, with the latest figure at $3.8 million for Q4 2017.

Quarterly results put Receivables at $3.8 million for Q4 2017, changed 0.0% from a year ago — trailing twelve months through Dec 2017 was $3.8 million (changed 0.0% YoY), and the annual figure for FY2017 was $3.8 million, changed 0.0%.
Receivables for Q4 2017 was $3.8 million at Northwest Biotherapeutics, roughly flat from $3.8 million in the prior quarter.
In the past five years, Receivables ranged from a high of $3.8 million in Q4 2016 to a low of $3.8 million in Q4 2016.